Home > Boards > US OTC > Biotechs > Sangamo Biosciences Inc. (SGMO)

$SGMO is pre-clinical with 3 current Phase 1/2

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Triple9 Member Profile
 
Followed By 55
Posts 1,194
Boards Moderated 2
Alias Born 01/13/17
160x600 placeholder
Sangamo et Pfizer annoncent des résultats de phase 1/2 mis à jour pour la thérapie génique expérimentale de l’hémoph... Business Wire - 7/8/2019 10:05:00 AM
Sangamo Therapeutics Up 17%; Unveiled Updated Study Data Dow Jones News - 7/8/2019 8:43:00 AM
Sangamo & Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained In... Business Wire - 7/5/2019 11:15:00 PM
 Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger P... Business Wire - 7/1/2019 11:00:00 AM
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019 PR Newswire (US) - 6/21/2019 9:16:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/18/2019 5:03:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:03:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:14:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:10:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:09:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:08:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:07:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:05:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 5:43:08 PM
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences PR Newswire (US) - 5/15/2019 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2019 8:02:59 AM
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference PR Newswire (US) - 5/10/2019 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 4:39:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 4:19:31 PM
Sangamo Therapeutics Reports First Quarter 2019 Financial Results PR Newswire (US) - 5/8/2019 4:01:00 PM
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast PR Newswire (US) - 5/1/2019 4:01:00 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/25/2019 4:36:32 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/25/2019 4:34:05 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 4/18/2019 6:48:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/17/2019 4:46:57 PM
Triple9   Wednesday, 09/27/17 11:56:45 AM
Re: None
Post # of 340 
$SGMO is pre-clinical with 3 current Phase 1/2 studies with data due by March 2018.

But the pipeline is very wide and this will be an interesting stock in the 3-5 year time frame.

Congrats to everyone who got aboard this train in the $5 range!!!

http://www.sangamo.com/product-pipeline



Know What You Own. My posts should not be construed as investment advice.
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist